about
Catechol-O-methyltransferase polymorphisms and some implications for cognitive therapeuticsAntipsychotic-induced sensitization and tolerance: Behavioral characteristics, developmental impacts, and neurobiological mechanismsCurious cases: Acromegaly and schizophrenia: an incidental association?Antipsychotic drugs on maternal behavior in rats.Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophreniaAsenapine sensitization from adolescence to adulthood and its potential molecular basisSelective effects of D- and L-govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophreniaFurther evidence for aberrant prefrontal salience coding in schizophrenia.Differential effects of intermittent versus continuous haloperidol treatment throughout adolescence on haloperidol sensitization and social behavior in adulthoodStructural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysisThe nature of relapse in schizophrenia.Pharmacogenetic tools for the development of target-oriented cognitive-enhancing drugs.Imaging genomics and response to treatment with antipsychotics in schizophrenia.Does lack of improvement in the first two weeks predict treatment resistance in recent-onset psychosis?Behavioral and emotional adverse events of drugs frequently used in the treatment of bipolar disorders: clinical and theoretical implications.Repeated administration of aripiprazole produces a sensitization effect in the suppression of avoidance responding and phencyclidine-induced hyperlocomotion and increases D2 receptor-mediated behavioral function.The use of antipsychotics in children and adolescents with bipolar disorders.Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism.Communication networks in the brain: neurons, receptors, neurotransmitters, and alcohol.Pharmacokinetics and metabolism update for some recent antipsychotics.Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.Synthesis and dual D2 and 5-HT1A receptor binding affinities of 5-piperidinyl and 5-piperazinyl-1H-benzo[d]imidazol-2(3H)-ones.Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions.Finding what you are not looking for: strategies for developing novel treatments in psychiatry.Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder.Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis.Asenapine induces differential regional effects on serotonin receptor subtypes.The effects of medication use in transcranial direct current stimulation: A brief review.Cognitive-Behavioural Interventions
P2860
Q24608073-97F30F35-764C-43BC-B528-6C77810C9F9AQ26745506-8ADF314B-74F9-44CC-B5A9-ACD101F8700EQ27025160-E1FBB68D-D2E5-44B9-A633-DB84BFE4A903Q30375083-07712330-2DD8-4D5E-989C-15BE39C1DFE4Q30375799-E58793C7-F65E-4072-A2C3-C931E3BD56F8Q30401078-E340915D-C16B-49E0-8BEF-DC59560E3ABFQ30578267-9114FAFD-E797-4775-BDF3-835F55DD2C35Q33650034-927694FC-1470-470E-AD55-FC00F2B18EFFQ34053684-4E116B10-DC6B-423A-9ACF-E0FAFB3521B4Q34393431-D16581FD-6794-45D6-B97E-049408457787Q34581127-674A0963-9426-4AC6-B3B3-6A15E854FDF7Q36401912-A6817C3B-8C88-4D40-8C7E-BE48AF4E3C11Q36401916-81BB14C7-95D1-446F-95B5-97F7F237771BQ36465378-6580CE97-E13F-4CFB-BC1F-B020A75F2926Q36582018-9C9D18F0-224E-45D8-9F52-0134F395F421Q36590407-2847FCDE-2FEA-47BD-A417-36D0217F7BBFQ36979293-B2CF4EA2-DF94-42A8-BCCF-796F8E40D8BFQ37338151-DFDA7218-8265-48B8-B4BC-D3253C362866Q37386620-FC3A4CCB-6DD8-41C6-882B-9AEE12449541Q37863118-6E2E8309-657D-4266-A5D7-F3611D78C1C0Q38992758-6DF5D26E-77B3-410B-88FC-C1F7C7FC8359Q39181392-D14FBAFF-164A-4568-B0DD-B0411D61CC89Q39917162-D4C69E12-7D3C-4BF1-B99C-AB43E5DBB353Q41358274-A206B892-4526-42D1-B1C0-B4ED990ECA62Q41809484-31C6207F-83ED-47E7-AE84-FA4F6FD37CC2Q41837878-0633B516-8DC4-4CD8-A5C4-FD955D5AFFD6Q46417433-F1F12422-4992-48BB-9EBD-E53399E674C4Q47729862-C038A15E-3661-4761-BC16-8E895D47A645Q57413652-552318B6-A9C7-4036-A920-BAE0BAC89392
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
How antipsychotics work-from receptors to reality.
@ast
How antipsychotics work-from receptors to reality.
@en
type
label
How antipsychotics work-from receptors to reality.
@ast
How antipsychotics work-from receptors to reality.
@en
prefLabel
How antipsychotics work-from receptors to reality.
@ast
How antipsychotics work-from receptors to reality.
@en
P2860
P1433
P1476
How antipsychotics work-from receptors to reality.
@en
P2093
Romina Mizrahi
P2860
P356
10.1016/J.NURX.2005.12.003
P577
2006-01-01T00:00:00Z